Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218357

SCHEMBL23218357

SCHEMBL23218357

CCOC(=O)CCc1ccccc1OCc1cc2cccc(Br)c2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 2/20 0.44
▸ CYP4A11 Q02928 2/20 0.44
▸ ALDH1A1 P00352 4/20 0.40
▸ HPGD P15428 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ MAPT P10636 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ FFAR4 Q5NUL3 2/20 0.38
▸ DHFR P00374 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CDYL Q9Y232 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218198 0.90 CFD (0.42) ALDH1A1HPGDKDM4EMAPTHTT
SCHEMBL23218442 0.81 CFD (0.46) CYP4F2CYP4A11ALDH1A1GAADHFR
SCHEMBL29852467 0.81 CFD (0.46) CYP4F2CYP4A11ALDH1A1GAADHFR
SCHEMBL23218790 0.81 CYP4F2 (0.44) CYP4F2CYP4A11ALDH1A1HPGDKDM4E
SCHEMBL29853252 0.79 TBXAS1 (0.43) ALDH1A1HPGDMAPTHTTMEN1
SCHEMBL23218663 0.79 TBXAS1 (0.43) ALDH1A1HPGDMAPTHTTMEN1
SCHEMBL23218558 0.78 TBXAS1 (0.42) ALDH1A1HPGDMAPTHTTMEN1
SCHEMBL23218819 0.78 CYP4F2 (0.39) CYP4F2CYP4A11ALDH1A1HPGDKDM4E
SCHEMBL29852888 0.78 CYP4F2 (0.39) CYP4F2CYP4A11ALDH1A1HPGDKDM4E
SCHEMBL23218761 0.75 CYP4F2 (0.46) CYP4F2CYP4A11ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CYP4F2 170/4885CYP4A11 523/4885ALDH1A1 2667/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CYP4F2 192/4885CYP4A11 466/4885ALDH1A1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.